Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01 - PubMed
5 hours ago
- #metastatic prostate cancer
- #PARP inhibitor
- #clinical trial
- Saruparib (AZD5305) is a next-generation, selective PARP1 inhibitor being tested in combination with androgen receptor pathway inhibitors (ARPIs) for metastatic hormone-sensitive prostate cancer (mHSPC).
- The EvoPAR-Prostate01 study is a Phase III, randomized, double-blind, placebo-controlled trial enrolling about 1800 participants, divided into cohorts with or without homologous recombination repair mutations (HRRm).
- Participants receive either saruparib plus an ARPI (abiraterone, darolutamide, or enzalutamide) or placebo plus an ARPI, alongside androgen deprivation therapy, with radiographic progression-free survival (rPFS) as the primary endpoint and overall survival (OS) as a key secondary endpoint.